HSDT
Helius Medical Technologies Inc Class A
2.60$
+0.0%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 130.8% | 67.2% | 91.1% | 64.8% | 366.7% | 101.3% | 246.9% | 223.3% | 14.8% | 3.4% | 5.0% | 3.0% | 4.5% | |
| -30.8% | 32.8% | 8.9% | 35.2% | -266.7% | -1.3% | -146.9% | -123.3% | 85.2% | 96.6% | 95.0% | 97.0% | 95.5% | |
| 504.9% | 485.1% | 583.7% | 478.0% | 2,111.8% | 607.9% | 1,928.6% | 1,911.6% | 123.1% | 16.9% | – | – | – | |
| 1,535.7% | 1,217.9% | 1,950.4% | 1,350.0% | 5,588.2% | 1,004.6% | 6,110.2% | 5,690.7% | 666.6% | 249.4% | 143.3% | 440.1% | 281.6% | |
| 2,174.1% | 1,709.0% | 2,539.3% | 1,831.9% | 7,713.7% | 2,069.1% | 8,038.8% | 7,602.3% | 789.7% | 266.3% | 143.3% | 440.1% | 296.0% | |
| -2,204.9% | -1,676.1% | -2,530.4% | -1,796.7% | -7,980.4% | -2,070.4% | -8,185.7% | -7,725.6% | -704.4% | -169.8% | -48.3% | -343.1% | -200.5% | |
| – | 50.7% | 5.9% | 2.7% | 2.0% | 2.0% | 12.2% | 1,460.5% | 0.1% | 24.3% | – | 2.7% | – | |
| -2,561.5% | -779.9% | -1,863.7% | -885.7% | -7,227.5% | -2,584.2% | -7,832.7% | -22,867.4% | -50,612.3% | 6,227.1% | -2,756.1% | -1,197.8% | -1,302.8% | |
| 472.7% | 0.0% | -20.2% | -8.8% | – | – | – | – | – | – | – | – | – | |
| -2,561.5% | -779.9% | -1,863.7% | -885.7% | -7,227.5% | -2,584.2% | -7,832.7% | -22,867.4% | -50,612.3% | 6,227.1% | -2,756.1% | -1,197.8% | -1,302.8% | |
| -2,064.3% | -764.2% | -1,845.9% | -874.2% | -7,194.1% | -2,036.2% | -7,816.3% | -21,386.0% | -50,517.1% | 6,227.1% | -2,756.1% | -343.1% | -1,118.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.